THBD and COVID-19: The frequency of CD141+DC (DC1), which are described as the most potent cross-presenting DC critical for an efficient anti-viral response (57), were not significantly changed in COVID-19 patients comparing to healthy donors in our study, and their role in SARS-CoV-2 has yet to be investigated.